Santen initiates phase 3 trials of omidenepag isopropyl for glaucoma, ocular hypertension

A pivotal phase 3 development program of omidenepag isopropyl for the treatment of glaucoma or ocular hypertension has been initiated by Santen Inc., the company announced in a press release.
The SPECTRUM 3 and SPECTRUM 4 trials, both randomized, double-masked, active-controlled, parallel-group, multicenter studies, will assess the efficacy and safety of omidenepag isopropyl 0.002% ophthalmic solution (DE-117), a selective agonist for the prostanoid receptor EP2, in comparison to timolol maleate 0.5%.
“Currently when glaucoma treatments fail, patients urgently need therapeutic options

Full Story →